Topline results from a phase 1/2 study of DE-122 suggest bioactivity of the agent in cases of refractory wet age-related macular degeneration, according to a press release from Santen.
The data were presented at Angiogenesis, Exudation, and Degeneration 2018 hosted by Bascom Palmer Eye Institute in Miami.
The open-label, dose-escalation, sequential-cohort study assessed the safety, tolerability and bioactivity of DE-122 (carotuximab) as a single intravitreal injection at four dose levels in 12 patients, three patients per dose, with AMD refractory to treatment with anti-VEGFs.
Study subjects
Uncategorized